U.S. Markets closed

Merck & Co., Inc. (MRK)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
76.14-0.73 (-0.95%)
At close: 4:00PM EDT
76.23 +0.09 (0.12%)
After hours: 04:12PM EDT
Sign in to post a message.
  • H
    Howie
    Second-Quarter 2021 Worldwide Sales from Continuing Operations (Excluding Organon) Were $11.4 Billion, 22% Above Second-Quarter 2020; Excluding the Impact from Foreign Exchange, Sales Grew 19% Reflecting Ongoing Recovery from the COVID-19 Pandemic and Strong Underlying Demand Across the Company’s Portfolio of Innovative Products:
    KEYTRUDA Sales Grew 23% to $4.2 Billion; Excluding the Impact from Foreign Exchange, Sales Grew 20%
    GARDASIL/GARDASIL 9 Sales Grew 88% to $1.2 Billion; Excluding the Impact from Foreign Exchange, Sales Grew 78%
    Animal Health Sales Grew 34% to $1.5 Billion; Excluding the Impact from Foreign Exchange, Sales Grew 27%
    Second-Quarter 2021 GAAP EPS from Continuing Operations Was $0.48; Second-Quarter 2021 Non-GAAP EPS from Continuing Operations Was $1.31
    Progressed Pipeline and Secured Multiple Regulatory Approvals, Including FDA Approval of VAXNEUVANCE, Merck’s 15-Valent Pneumococcal Conjugate Vaccine, for Adults; FDA Approvals for Neoadjuvant/Adjuvant KEYTRUDA in Combination With Chemotherapy for High-Risk Early-Stage Triple-Negative Breast Cancer (KEYNOTE-522) and KEYTRUDA in Combination with Lenvima for the Treatment of Certain Patients With Advanced Endometrial Carcinoma (KEYNOTE-775/Study 309)
    Completed the Spinoff of Organon on June 2; Received Cash Distribution of Approximately $9 Billion
  • L
    LGALS3
    This is great news because developments like this could provide a way to extend the Keytruda patent well into the future, plus expand the number of patients who can benefit.
    https://www.dermatologytimes.com/view/belapectin-pembrolizumab-show-early-activity-tolerability-in-metastatic-melanoma
    Bullish
  • e
    ed
    Unfortunately the market can remain irrational a lot longer than an individual can stay liquid. I do not understand MRK at $76. I think the market needs good news on the approval of the Covid anti viral? Maybe I am just missing the entire picture. Keep holding. MRK was above $90 a couple years back and Keytruda is a bigger blockbuster now than then….
    Bullish
  • A
    Anonymous
    Not just CEO. Entire management and their teams are in "comfort zone" with Keytruda. Culture and vision problems? Yesterday, Pfizer raised covid vaccine revenue from $24B to $33B in 2021 alone. Wake up Merck.
  • m
    markm
    sga expenses increased 9%....unreal.
  • j
    jim
    $SLS conversation
    Upcoming catalysts: Multi Billion dollar Gps FDA approval for AML 5.5 months $cpxx $1.5B comp
    - $Glsi type trial data for Nps in combination wHerceptin Aug completion, GLSI added a billion in Market cap
    - Gps + Opdivo Final trial data for Ovarian Cancer ( not to be confused with the Key combo) due any day
    - Vadis Nps dcis final data is also due - NCT Site Updated this week
    - Phase 3 $MRK $SLS OC Partnership and Trial announcement
    - Many possible licensing deals Eu Asia Japan - Many Possible Trial Enrollment Updates
    - $200M milestone money news, expecting $10 more million this year and $40M next
    - Additional partnership announcements,
    - new trials launching, -fda breakthrough and orphan designation status granted /
    - Merck buyout news -Bmy partnership and or buyout news
    - Gps + Keytruda for OC 5.5 months
    - Gps + Opdivo for Meso 5.5 months
    Bullish
  • d
    dennis
    22% growth.
  • C
    Charles
    This is bad non-performance you get when you don't pick the best and brightest scientific minds for CEO.
  • v
    vlad
    How is anyone shocked that Merck missed? Spinoff? Anyone?
  • C
    Cracker
    CFRA maintains buy opinion on MRK with a $90 PT
  • R
    Robert
    What or who is holding this stock back?
    Hard to believe one of the premier companies in the world continues to be a under performer.
  • R
    Rex
    No worries…$80 stock 🔜
    Bullish
  • r
    raymond
    pfizer ate their lunch. no way mrk should not have had a vaccine. first they gave moderna hundreds of
    millions for part of the company years ago. plus they are in co development of drugs using m rna technology
    so what happened? frazier believed that chinezze lover tedros . while frazier was getting something kissed by tedros for the ebola vaccine.......the vaccine people at merck where being gagged and held back
  • s
    steve b
    I purchased 50 shares Merck around 25 years ago, yes it did split, but it has under preformed for myself for way too many years, compared to MSFT and AMZN, and even Costco the last 4 years.
  • S
    Samantha
    At some point the market will have to realize how valuable this company is. I may not be alive still but at some point it will happen.
  • K
    Kevin
    I just bought 2,750 shares guys and hope to see the best news here shortly!
    illed Buy 2750 MRK Market 76.0464 -- -- 12:51:18 07/21/21
  • C
    CASHRUS
    Missed again??? The people that run this have to go.
  • M
    Mary
    This company is heavily manipulated. I feel like government doesn't want this stock to go up glad I sold mine. Feel bad for my friend though sure he gets dividend but he didn't make anything off merck during this pandemic. I don't know if there are too many shares out there or if government is just manipulating it. Disappointing indeed. Good luck guys.
  • o
    oksana
    Found 6/19/21 Zacks report with $66 target downgrade to underperform.
    Merck’s drugs like Keytruda, Lynparza and Bridion have been driving sales. Animal health and vaccine products remain core growth drivers. The separation into two companies makes strategic sense as the remaining Merck should be able to achieve higher profits than the combined company. However, generic competition for several drugs and rising competitive pressure, mainly on the diabetes franchise,
    will continue to be overhangs on the top line. Rising competition in the oncology market is also a significant
    concern. Merck has also had its share of pipeline and regulatory setbacks. Merck’s shares have underperformed the industry this year so far. Estimates have declined significantly ahead of Q2 results. Merck has a mixed record of earnings surprises in recent quarters.
    Bearish
  • A
    Anonymous
    Recently, Pfizer stock was much stronger than Merck and is helped likely by its covid vaccine sale. They believe they can make $20B revenue in 2021 alone. Merck earned zero. $20B is a lot. Merck may earned few pennies from renting facilities. Strange strategy.
    Neutral